Stay updated with breaking news from Alan List. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final...
Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T... | May 31, 2023
- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel- Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T DoseDURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences (Nasdaq:...
DURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the company’s le...
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed SubjectsPBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologous CAR T Peak Expansion in Long Term Durable RespondersPBCAR19B CAR T Cell Manuf...